<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810990</url>
  </required_header>
  <id_info>
    <org_study_id>CML1516</org_study_id>
    <secondary_id>2016-002216-40</secondary_id>
    <nct_id>NCT02810990</nct_id>
  </id_info>
  <brief_title>Bosutinib in Elderly Chronic Myeloid Leukemia</brief_title>
  <acronym>BEST</acronym>
  <official_title>Bosutinib Efficacy, Safety, Tolerability (BEST) Study in Elderly Chronic Myeloid Leukemia Patients Failing Front-line Treatment With Other Tyrosine Kinase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to evaluate a new drug called bosutinib as it is
      believed that this agent may be able to predict an excellent prognosis in patients that did
      not obtain any benefit with other drugs before. Still, this needs to be proved and we hope
      this study is able to do so.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bosutinib is a potent tyrosine kinase inhibitor (TKI) active at nM concentration on BCR-ABL1
      and most BCR-ABL1 mutations. Bosutinib has been approved by the FDA and the EMA for the
      treatment of patients with Ph+/BCR-ABL1+ chronic myeloid leukemia who fail treatment with
      other TKIs, first or second line. The goal of second-line treatment of CML is to achieve a
      response that would predict for a survival equal to, or very close to, the survival of non
      leukemic people, that is to say to achieve a complete cytogenetic response (CCyR) or a major
      molecular response (MMR). To achieve that goal, it is necessary to find and keep the right
      balance between activity, safety, and tolerability. There are no studies comparing TKIs in
      second-line. From phase 2, single-arm, studies, the reported efficacy of Bosutinib is similar
      to the reported efficacy of dasatinib and nilotinib. The median age of newly diagnosed CML
      patients is about 56 years, and at least 40% of all newly diagnosed patients are more than 60
      years old. Particularly for these patients, the choice of the TKI must take into account the
      safety and the tolerability profile of the TKIs. The use of dasatinib and nilotinib is
      burdened by pleural and pulmonary complications, by infections, and by cardiovascular,
      thrombotic and metabolic (diabetes mellitus, dyslipidemia) complications. These complications
      are more frequent and more clinically relevant in the elderly. The safety and tolerability of
      Bosutinib has been reported in first- as well as in second- and third-line. The standard dose
      (500 mg once daily) is tolerated and safe, but at that dose several adverse events (AEs)
      limit the tolerability, require dose reduction or interruption, and affect patient quality of
      life, including diarrhea, nausea, vomiting, skin rash. Also an increase of AST, ALT and
      lipase are of concern and a cause of treatment discontinuation. On the contrary, an increased
      frequency of infections and of pleuro-pulmonary, cardiovascular, thrombotic, and metabolic
      AEs has not been reported. The reported hematologic toxicity of Bosutinib is at least as low
      as, or even lower than, that reported for the other TKIs, in spite of the fact that Bosutinib
      is a dual, BCR-ABL1 and src inhibitor. Until today, all studies of TKIs in CML have tested a
      fixed initial dose, providing for dose adjustment in case of toxicity (dose decrease) or in
      case of unsatisfactory response (dose increase). No study so far was designed to test the
      adaptation of the dose to the response, taking advantage of the fact that the efficacy of TKI
      treatment can be assessed rapidly and precisely by measuring the BCR-ABL1 transcripts level
      with real-time PCR (RT-PCR) in peripheral blood cells. An RT-PCR monthly for the first few
      months provides the best assessment of the response to treatment. We predict that a more
      flexible strategy of treatment (adapting the dose to the response) will result into a more
      convenient balance between activity and toxicity, hence into a better outcome. Based on these
      premises, it is proposed to test the activity, the safety, and the tolerability of Bosutinib,
      second-line, beginning with a low dose and adjusting subsequent doses based on molecular
      response, and on AEs, in a population of elderly patients. In almost all prior studies of
      TKIs in second- or third-line, the primary efficacy was assessed using cytogenetic response,
      both major and complete, at different time points. To make the results of this study
      comparable to the results of prior studies, the cytogenetic response will be evaluated as
      specified in section 5, but since the response to therapy and the evaluation of the efficacy
      of therapy are more and more based on molecular response, dose adaptation and efficacy
      evaluation will be based primarily on molecular response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who are in major molecular response (MMR)</measure>
    <time_frame>One year treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who obtain molecular response</measure>
    <time_frame>At 6 and 12 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients discontinuing treatment for failure, adverse events or other reasons</measure>
    <time_frame>At 12 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>At 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive</measure>
    <time_frame>At 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients on treatment at 200, 300 and 400 mg or more daily</measure>
    <time_frame>At 6, 12 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and type of BCR-ABL1 mutations</measure>
    <time_frame>At 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported quality of life</measure>
    <time_frame>At 3, 6, and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Bosutinib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>Bosutinib is given orally accordingly with this scheme:
A. 200 mg OD: starting dose (&quot;wash-in&quot; period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16
At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).
Bosutinib dose is then managed as follows :
C1. if BCR-ABL1 â‰¤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 &gt; 1% at week 12: 400 mg OD from week 17 to week 52
All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns).</description>
    <arm_group_label>Bosutinib treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Molecular confirmed diagnosis of BCR-ABL1+ CML

          2. Chronic phase CML (ELN 2013 criteria)

          3. 60 years of age or older

          4. Prior first-line treatment with any other TKIs

          5. Intolerance to prior treatment, based on investigator and patient assessment or
             failure of prior treatment according to any one of the ELN 2013 criteria, as listed
             below

               -  Non complete hematologic response (CHR) at 3 months

               -  No cytogenetic response (Ph+ &gt; 95%) at 6 months

               -  Less than Partial Cytogenetic Response (PCyR) (Ph+ &gt;35%) at 6 months

               -  BCR-ABL1 &gt; 10% at 6 months

               -  Non complete CyR (CCyR) (Ph+ &gt; 0) at 12 months

               -  BCR-ABL1 &gt; 1% at 12 months

               -  Loss of CHR at any time

               -  Loss of CCyR at any time

               -  Confirmed loss of major molecular response (MMR) (BCR-ABL1 &gt; 0.1%) in two
                  consecutive tests, of which one &gt; 1%, at any time

          6. An effective form of contraception from enrolment through 30 days after the end of
             treatment

          7. Signed written informed consent according to ICH/EU/GCP and national and local laws
             prior to any study procedures

          8. Willingness and ability to comply with scheduled visits and study procedures.

        Exclusion Criteria:

          1. Accelerated or blastic phase CML (according to ELN 2013 criteria)

          2. Patients with the T315I or the V299L mutation

          3. Patients previously treated with 2 TKIs or more

          4. Compelled to take medications that are known to be associated with Torsades de Pointes
             and/or with significant QTc prolongation

          5. Any condition or illness that, in the opinion of the Investigator, would compromise
             patient safety or interfere with the evaluation of the drug

          6. HBV markers positivity

          7. Lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianantonio Rosti</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology and Hematology, O.U. of Hematology, S. Orsola-Malpighi University Hospital, Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pini</last_name>
    </contact>
    <investigator>
      <last_name>Pini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupoli</last_name>
    </contact>
    <investigator>
      <last_name>Rupoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-UniversitÃ  degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Specchia</last_name>
    </contact>
    <investigator>
      <last_name>Specchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology and Hematology, O.U. of Hematology, S. Orsola-Malpighi University Hospital, Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianantonio Rosti</last_name>
    </contact>
    <investigator>
      <last_name>Gianantonio Rosti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosti</last_name>
    </contact>
    <investigator>
      <last_name>Rosti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usala</last_name>
    </contact>
    <investigator>
      <last_name>Usala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stagno</last_name>
    </contact>
    <investigator>
      <last_name>Stagno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia ASO S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rapezzi</last_name>
    </contact>
    <investigator>
      <last_name>Rapezzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cavazzini</last_name>
    </contact>
    <investigator>
      <last_name>Cavazzini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bosi</last_name>
    </contact>
    <investigator>
      <last_name>Bosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia Ospedali Riuniti Foggia</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Capalbo</last_name>
    </contact>
    <investigator>
      <last_name>Capalbo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11Â°piano- lato ponente</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gobbi</last_name>
    </contact>
    <investigator>
      <last_name>Gobbi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucchesi</last_name>
    </contact>
    <investigator>
      <last_name>Lucchesi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Musolino</last_name>
    </contact>
    <investigator>
      <last_name>Musolino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iurlo</last_name>
    </contact>
    <investigator>
      <last_name>Iurlo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciceri</last_name>
    </contact>
    <investigator>
      <last_name>Ciceri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UnitÃ  Trapianto di Midollo Ist. Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corradini</last_name>
    </contact>
    <investigator>
      <last_name>Corradini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S.Gerardo&quot;</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gambacorti</last_name>
    </contact>
    <investigator>
      <last_name>Gambacorti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda UniversitÃ  degli Studi di Napoli &quot;Federico II&quot; - FacoltÃ  di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pane</last_name>
    </contact>
    <investigator>
      <last_name>Pane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - UniversitÃ  del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lunghi</last_name>
    </contact>
    <investigator>
      <last_name>Lunghi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rege Cambrin</last_name>
    </contact>
    <investigator>
      <last_name>Rege Cambrin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  degli Studi di Padova - Ematologia ed Immunologia Clinica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Binotto</last_name>
    </contact>
    <investigator>
      <last_name>Binotto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia con trapianto - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siragusa</last_name>
    </contact>
    <investigator>
      <last_name>Siragusa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO UniversitÃ  degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crugnola</last_name>
    </contact>
    <investigator>
      <last_name>Crugnola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cazzola</last_name>
    </contact>
    <investigator>
      <last_name>Cazzola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vallisa</last_name>
    </contact>
    <investigator>
      <last_name>Vallisa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pizzuti</last_name>
    </contact>
    <investigator>
      <last_name>Pizzuti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico - Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvucci</last_name>
    </contact>
    <investigator>
      <last_name>Salvucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UnitÃ  Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Capodanno</last_name>
    </contact>
    <investigator>
      <last_name>Capodanno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molinari</last_name>
    </contact>
    <investigator>
      <last_name>Molinari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia - Centro Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pietrantonio</last_name>
    </contact>
    <investigator>
      <last_name>Pietrantonio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedrone</last_name>
    </contact>
    <investigator>
      <last_name>Cedrone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia - UniversitÃ  Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>De Muro</last_name>
    </contact>
    <investigator>
      <last_name>De Muro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Padiglione Cesalpino - I piano - Divisione di Ematologia - Ospedale S. Camillo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mancini</last_name>
    </contact>
    <investigator>
      <last_name>Mancini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SorÃ </last_name>
    </contact>
    <investigator>
      <last_name>SorÃ </last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Pronto Soccorso - Dipartimento Biotecnologie Cellulari UniversitÃ  di Roma &quot;Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Breccia</last_name>
    </contact>
    <investigator>
      <last_name>Breccia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. G. Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cascavilla</last_name>
    </contact>
    <investigator>
      <last_name>Cascavilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bocchia</last_name>
    </contact>
    <investigator>
      <last_name>Bocchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liberati</last_name>
    </contact>
    <investigator>
      <last_name>Liberati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - &quot;CittÃ  della Salute e della Scienza di Torino&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferrero</last_name>
    </contact>
    <investigator>
      <last_name>Ferrero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia 2 A.O. CittÃ  della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pregno</last_name>
    </contact>
    <investigator>
      <last_name>Pregno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica-Centro Trapianti e Terapie cellulari</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiribelli</last_name>
    </contact>
    <investigator>
      <last_name>Tiribelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medicina Interna I - Ospedale di Circolo</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Passamonti</last_name>
    </contact>
    <investigator>
      <last_name>Passamonti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonifacio</last_name>
    </contact>
    <investigator>
      <last_name>Bonifacio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bosutinib</keyword>
  <keyword>chronic myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

